Manufacturer
APOTEX INC
Contents
Perphenazine
Indication
Severe Nausea and Vomiting, Mania, Psychoses and Schizophrenia.
Instruction
Should be taken with food.
Drug interaction
Increased plasma concentration when given w/ ritonavir or TCAs. Inhibit metabolism of perphenazine when taken w/ paroxetine. Absorption may be reduced w/ kaolin or antacids. Reduced effects w/ memantine. Additive hypotensive effects w/ antihypertensive agents. Risk of sedation or toxicity w/ CNS depressants (e.g. other antipsychotics, opioids, sedatives, antihistamines). Increased risk of convulsion when used w/ tramadol. Increased risk of extrapyramidal reaction when used w/ lithium, metoclopramide and fluoxetine. May antagonise the therapeutic effects of anticonvulsants and drugs used for movement disorders (e.g. Parkinson’s disease). Antagonises the hypoglycaemic effect of sulfonylureas. May increase the absorption of corticosteroids and digoxin. May increase bleeding time when used w/ anticoagulants. Increased risk of toxicity when used w/ myelosuppressive agents.Potentially Fatal: Additive sedative effects and/or toxicity when taken concomitantly w/ large doses of other CNS depressants (e.g. barbiturates, antihistamines, narcotics, analgesics).
Malaysia
